Introduction
All cause mortality increases with lower levels of estimated glomerular filtration rates. As part of a comorbidity focus, we assessed the eGFR in CSF-flow disorder patients guided by NICE recommendations, current literature recognising a relative hazard ratio per 15mls/min decrease in eGFR of 1.04 [1] and consideration of the 2010 Chronic Kidney Disease Epidemiology Collaboration eGFR categories.
Methods
182 CSf-flow disorder patients who had eGFR measurement were grouped into the respective subtypes; IIH (n=41), NPH (n=72), CSF hypovolaemia (n=7) and other causes (n=45). Others included those investigated for NPH but found not to be suitable for shunt.
Estimated GFR was categorised as per NICE guidelines; (ml/min/1.73m) in line with current clinical laboratory facilities;
>90 normal high, 60-89 mild reduction related to normal range for a young adult, 45-59 mild-moderate reduction, 30-44 moderate-severe reduction, 15-29 severe-reduction, <15 kidney failure. The eGFR's were recorded and the mean calculated for each subgroup. Orthostatic HA; mean eGFR 87.25mls/min; 5 patients >90 normal high and 2 patients 60-89 mild reduction.
Results
Other cohort; mean eGFR 76.96mls/min; 22 patients >90, 21 patients 60-89 mild reduction and 2 patients 45-59 in the moderate-severe reduction.
Of the 182 patients, 71 patients had high normal eGFRs >90mls/min representing 39% of patients. 48% fell into the 60-89 mild reduction range, 11.5% into the 45-59 mild-moderate reduction range and 1% into the moderate-severe reduction range.
Conclusions
A reduced estimated GFR is commonly seen in the CSFflow disorders patient cohorts. Given the emphasis towards comorbidity factors influencing surgical outcomes, this acts as a marker of comorbidity and physiological reserve for surgical tolerance and post-operative performance and should therefore be taken into consideration.
The altered eGFR could represent the comorbid state of the patient or it could form an element of the underlying pathophysiology of CSF-flow disorders or indeed * Correspondence: patriciahaylockvize@gmail.com The National Hospital for Neurology and Neurosurgery, UK
